Join us in London to explore cutting-edge patient-centric approaches. This premier event gathers industry leaders, healthcare innovators, and patient advocates to discuss collaboration that truly impacts healthcare delivery. Our team will present insights on advancing patient engagement through actionable strategies. Engage with workshops, network with experts, and participate in dialogues that aim to reshape healthcare by prioritizing patients. Schedule a meeting with us to delve into meaningful collaborations.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
